GEN Exclusives

More »

GEN News Highlights

More »
Mar 2, 2009

Pfizer Taps Xencor for Antibody-Optimizing Technology

  • Pfizer will evaluate the application of Xencor’s Xtend™ antibody half-life prolongation technology and XmAb® ADCC enhancing technology in several of its discovery projects. In addition, Pfizer has taken a commercial license to Xencor’s technology for one program.

    Xencor will receive an up-front payment and is eligible to considerations based on the successful commercialization of products that incorporate the Xencor technology.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?